Open AccessWhat Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?
Author(s) -
Salih Tokmak,
Yüksel Gümürdülü,
Didem Arslan Taş,
İbrahim O Kara,
Ahmet Barış Güzel
Publication year - 2021
Publication title -
the turkish journal of gastroenterology/the turkish journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 28
eISSN - 2148-5607
pISSN - 1300-4948
DOI - 10.5152/tjg.2021.201131
Subject(s) - medicine , rituximab , hepatitis b virus , antibody , group b , gastroenterology , hepatitis b , prospective cohort study , immunology , virus
Reactivation of Hepatitis B (HBVr) related to immunosuppressive drug therapy (ISDT) in patients with resolved and past infection is a challenging entity. The number of prospective long-term studies is limited.